` tags.
`
- Lenire is the proud sponsor of the LexCare Hearing Foundation’s 10th Annual Hearoes Tour.
- Lenire offers a treatment option for the 3.2m veterans who suffer from tinnitus.
CHICAGO, April 7, 2025 — Lenire, the first tinnitus treatment device of its kind to receive FDA approval, proudly supports the 10th Annual LexCare Hearing Foundation Hearoes Tour. The tour aims to increase awareness and improve access to hearing and tinnitus care for US Veterans.
The Hearoes Tour is a nationwide initiative providing free hearing health resources, screenings, and guidance directly to veteran communities throughout the United States.
The Hearoes Tour hosts over 200 events each year, breaking down barriers to hearing and tinnitus care by simplifying the process, addressing cost concerns, increasing awareness of the consequences of untreated hearing loss, and improving access to treatment. To date, the Hearoes Tour has provided over 33,000 hearing screenings and organized more than 1,000 free hearing health events.
According to Jaime Motes, Founder/Director of The LexCare Hearing Foundation, “Nearly 40% of the veterans we’ve assisted through the Hearoes Tour have reported experiencing tinnitus, yet for many years, we lacked an effective solution to offer them.”
Motes added, “This is a cause close to my heart as my daughter has cochlear implants due to being born deaf. She has a solution. Every veteran deserves a solution. Now, finally, we can provide one. Thanks to our partnership with Lenire, we can connect veterans with a potentially life-changing tinnitus treatment after years of advocacy, awareness efforts, and outreach.”
“This partnership marks a significant step in our mission to remove obstacles to hearing and tinnitus care, offering genuine hope and practical solutions for those who have given so much.”
Tinnitus: The Most Prevalent Service-Connected Disability
Since 1955, tinnitus has remained the most common service-connected disability compensated by the VA. In 2024, veterans received approximately $6.6 billion in service-connected compensation for tinnitus.1 Tinnitus accounted for 63% of all auditory Veteran Compensation Claims.1
Neuromod, the company that created Lenire, was awarded a making Lenire a possible treatment for 3.2 million Veterans with tinnitus via the Department of Veterans Affairs.1
Lenire is the first bimodal neuromodulation device for tinnitus to be awarded a Federal Supply Schedule (FSS) Contract. Currently, 50 USVA facilities have been trained to administer Lenire treatment, with more training sessions planned for 2025.
Eric Timm, Neuromod USA CEO and Neuromod Devices President of Global Commercial Operations, stated, “Sponsoring the 10th Annual Hearoes Tour and supporting the valuable services provided by The Lexcare Hearing Foundation furthers our commitment to veterans by increasing awareness and accessibility to transformative hearing and tinnitus care treatment options.”
A New Era in Tinnitus Treatment
A growing body of real-world evidence demonstrates the positive outcomes for thousands of tinnitus patients successfully treated with Lenire at independent USA-based clinics.
The initial findings from Alaska Hearing & Tinnitus Center, which will be the first in a series of planned real-world evidence publications, revealed that 91.5% of 220 patients reported a clinically significant improvement in their tinnitus.2
These findings are consistent with and, in many cases, exceed the data from Lenire’s extensive clinical trials.
These results were preceded by the publication of Lenire’s pivotal controlled clinical trial results, which secured De Novo US FDA approval and were featured as the cover story in the peer-reviewed journal, Nature Communications.3 This article ranks in the 99th percentile of over 250,000 tracked Nature articles.
About Neuromod
Established in 2010, Neuromod Devices Ltd. is a medical technology company based in Dublin, Ireland. Neuromod specializes in the design, development, and commercialization of neuromodulation technologies that address the unmet clinical needs of patients suffering from chronic and debilitating conditions.
Neuromod’s primary focus is in the field of tinnitus, where the company has conducted comprehensive clinical trials to validate the effectiveness of its non-invasive neuromodulation platform for this prevalent condition. For more information, please visit .
About Tinnitus
Tinnitus, often described as ‘ringing in the ears’, is a complex neurological condition characterized by the perception of sound in the absence of an external source. It is estimated that tinnitus affects approximately 15% of adults worldwide.
About Lenire
Lenire is the first non-invasive bimodal neuromodulation device for tinnitus proven to alleviate and relieve tinnitus symptoms in a large-scale clinical trial. Lenire functions by delivering gentle electrical pulses to the tongue via an intra-oral component called the ‘Tonguetip®’, combined with auditory stimulation through headphones. This dual stimulation approach facilitates changes in the brain to treat tinnitus. To date, Lenire has been evaluated in large-scale clinical trials involving over 700 patients.
Lenire holds CE-mark certification for tinnitus treatment under the guidance of a qualified healthcare professional in Europe and has received De Novo approval from the US FDA. Further information on Lenire and Clinical Providers is available at .
References
1.
2.
Photo –
SOURCE Neuromod Devices